[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BowTiedBiotech Avatar @BowTiedBiotech BowTiedBiotech 🧪🔬🧬

BowTiedBiotech 🧪🔬🧬 posts on X about $pfe, $lly, $nvs, $azn the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXXX% finance XXXX% currencies #3705 countries XXXX% cryptocurrencies XXXX% technology brands XXXX% vc firms XXXX%

Social topic influence $pfe #41, $lly #18, $nvs #2, $azn #21, $rhhby #2, $biib #17, novartis #6, $sny #20, approved 0.4%, $14b #41

Top accounts mentioned or mentioned by @biopharmiq @bioinvestor24 @andre_agtc @wallstsai @pjamess69 @grok @yaireinhorn @varro_analytics @duedoctor @aasgardinvest @eperlste @dboral @jessiechimni @aaronrosenblum5 @amaymd @mykalt45 @oneworld1383 @andreagtc @biobrainbox @persimmonti

Top assets mentioned Pfizer, Inc. (PFE) Eli Lilly and Company (LLY) Novartis AG (NVS) AstraZeneca PLC (AZN) Biogen Inc (BIIB) Synthetify (SNY) Gilead Sciences, Inc. (GILD) Amgen, Inc. (AMGN) GSK plc (GSK) Novo-Nordisk (NVO) Akropolis (AKRO) Tourmaline Bio, Inc. Common Stock (TRML) Johnson & Johnson (JNJ) Viking Therapeutics, Inc (VKTX) AbbVie Inc (ABBV) Sanofi (SNY) Merck & Co., Inc. (MRK) One Cash (ONC) uniQure N.V. (QURE) BEAM (BEAM) CRISPR Therapeutics AG (CRSP) Intellia Therapeutics, Inc (NTLA) Tempus AI, Inc. Class A Common Stock (TEM) Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Bristol-Myers Squibb Co (BMY) Thermo Fisher Scientific Inc. (TMO) Jazz Pharmaceuticals, Inc. (JAZZ) Viking Holdings Ltd (VIK)

Top Social Posts #

Top posts by engagements in the last XX hours

"Your Weekly Biotech News Fix Ep. XXX 🤖 Listen to the AI robots objectively debate this weeks top biotech news. 🍽 Oral obesity pill race heats up 💼 Big Pharma layoffs top 39000 🧬 $RHHBY buys $ETNB for $3.5B 🏭 $GSK invests $30B in U.S. R&D ⚗ $LLY builds $5B Virginia plant 🧠 $BIIB acquires Alcyone for RNA delivery 🧩 VectorY$SHAPE $1.2B brain capsids 📊 $LLY obesity pill late-stage data 💊 $LXRX advances non-opioid pain drug 📺 FDA cracks down on GLP-1 ads 👁 Ollin Bio debuts with $100M 🔗 Links to podcast: Substack: Spotify:"
X Link @BowTiedBiotech 2025-09-19T16:00Z 20.9K followers, 1826 engagements

"4/ 📈 Impact on Swiss Pharma Stocks 🔹 Roche $RHHBY XX% of sales from US 🔹 Novartis $NVS XX% of sales from US 🔹 Lonza $LZAGY XX% of rev from US CDMO 🔹 Sandoz $SDZNY XX% US exposure 🔹 Galderma $GALD US is top aesthetics market (40%) All had a tariff discount priced in. Thats now unwinding"
X Link @BowTiedBiotech 2025-07-05T11:31Z 20.9K followers, 1034 engagements

"🚨 BTD Moonshot Two more Breakthrough Therapy Designations hit the tape: $ONC Sonrotoclax (BCL-2i MCL) $BCAX Ficerafusp (EGFR x TGF 1L HPV HNSCC) Both stocks popped but nowhere near the outsized reactions we saw last week. Heres why 👇🏼 1The Market Already Knew Investors had been expecting these BTDs. Both drugs showed strong early data and were in active FDA communication. When everyones positioned for good news even great news just confirms whats priced in. 2Risk Isnt Gone BTD lowers regulatory friction but doesnt remove clinical risk. Sonrotoclax still needs to differentiate from $AABV"
X Link @BowTiedBiotech 2025-10-14T10:49Z 20.9K followers, 5976 engagements

"Discovered in China Scaled in America: The $6B Cancer Deal That Could Reshape ChinaUS Biotech $PFE just paid $1.25B upfront to license a PD-1 x VEGF bispecific from Chinas 3SBio. Its one of the richest Chinese biotech deals ever. But this isnt about one molecule. Its a blueprint for what comes next. Lets break it down:"
X Link @BowTiedBiotech 2025-05-22T11:42Z 20.9K followers, 20.9K engagements

"$NVO buys $AKRO for up to $5.2B Another example of the new M&A template: mid-size milestone-linked and franchise-aligned. Deal terms: Upfront: $54/share (16% premium) CVR: +$6/sh if approved by 2031 Total: Up to $5.2B Lead asset: efruxifermin (FGF21 agonist) Ph3 MASH Strategic fit: Adds liver & metabolic optionality to $NVOs GLP-1 franchise 🧐Lets look at the emerging trends: Deal size sweet spot: Most 2025 biotech M&A sits between $26B (e.g. $MRK - $SWTX $3.9B $SNY - $VIGL $470M $LLY - $VERV $1.3B). Big pharma wants clinical-stage leverage without paying $10B premia. CVRs are back: XX% of"
X Link @BowTiedBiotech 2025-10-09T11:01Z 20.9K followers, 9969 engagements

"👀 $BIIB exiting AAV"
X Link @BowTiedBiotech 2025-09-26T10:47Z 20.9K followers, 2672 engagements

"The obesity takeover. In 2028 the LOE fun begins with top dog Keytruda and Eliquis coming under pressure. Obesity generics are about a decade out.🤑"
X Link @BowTiedBiotech 2025-08-24T12:20Z 20.9K followers, 13.7K engagements

"1/ Big Pharma is betting inflammation = the next cholesterol. $NVS just spent $1.4B buying $TRML for its IL-6 asset. 👀 Everyones watching obesity drugs but atherosclerosis is lining up as the next mega-blockbuster. Skip to post 7&8 and we get into where this is all headed by 2035 Lets discuss 🧵"
X Link @BowTiedBiotech 2025-09-13T11:54Z 20.9K followers, 10.1K engagements

"Biotech Microcap Mania $SPRB +1400% Still odd price action off BTD 🤷♂"
X Link @BowTiedBiotech 2025-10-06T20:23Z 20.9K followers, 3304 engagements

"Your Weekly Biotech News Fix Ep. XXX 🧬 $IMRX: Atebimetinib + chemo XX% 9mon OS PDAC ⚖ FDA: Drafts to speed cell/gene dev. 💰 $SNY: +$625M VC total $1.4B rare/neuro. 🏭 $JNJ: FDA warns Korea site GMP lapses. 🧪 $BIIB: Hi-dose Spinraza CMC rejection. 🌎 H-1B: $100K fee risks biopharma hires. 🏗 $LLY: $6.5B Houston plant oral GLP-1. 🧠 $QURE: AMT-130 slows HD XX% BLA XX. 👶 FDA: Revives Wellcovorin Tylenol preg risk. 💉 $LXRX: Zynquista T1D delayed to Q4"
X Link @BowTiedBiotech 2025-09-26T16:00Z 20.9K followers, 2302 engagements

"🚨 INNOVATORS take note A fresh $325M for biotech innovation. Although this fund has been open from 2023-25 so not exactly a new kid on the block. Goes to show how hard it is to raise in this environment but it can be done"
X Link @BowTiedBiotech 2025-10-10T11:31Z 20.9K followers, 1276 engagements

"🚨 Big news: $PRME (Prime Medicine) just jumped into the Alpha-1 Antitrypsin Deficiency (AATD) race with gene-editing firepower. 🧬 With a $20B TAM and a packed field can a latecomer cash in Lets break down the modalities peak sales and runway. 🧵👇"
X Link @BowTiedBiotech 2025-03-18T11:45Z 20.9K followers, 10K engagements

"$GUTS Fractyls dual GIP/GLP-1 gene therapy (RJVA-002) looks impressive on slides XX% body-weight loss in X weeks in DIO mice. Real efficacy. But its also a biological minefield. 💡The Pitch AAV vector delivering GIP + GLP-1 driven by an insulin promoter only active when glucose high. The pancreas becomes a self-titrating incretin pump. One shot no injections lifelong effect. A gene-encoded Mounjaro. 😌The Problem Works because -cells secrete incretins.but those same -cells are already overworked in obesity. No dose control. No reversibility. Elegant on paper; unforgiving in practice. 🐭The"
X Link @BowTiedBiotech 2025-10-07T11:32Z 20.9K followers, 15.6K engagements

"Is AI Outperforming Graduate Students in Science Ep. XXX 🤖 Listen to the robots talk about robots replacing humans 📣🎙 TODAYS PODCAST: 0:00 Welcome 1:09 A bottleneck for discovery 1:32 Where AI is changing the game 2:31 PaperQA2 surpasses humans 5:24 Skepticism replaces confirmation 6:19 WikiCrow raises the bar 8:08 AI becomes a virtual lab partner 10:47 Amplifying human scientists 12:47 A global democratized future 🔗 links to podcast: Substa*ck Spotfy:"
X Link @BowTiedBiotech 2025-10-15T12:31Z 20.9K followers, XXX engagements

"🧬 X REASONS WHY GENETIC MEDICINE IS BACK $ARKG +42% last 6mon X $BEAM + $CRSP + $NTLA now make up XX% of $ARKG Investors are rotating back into precision editing after a brutal 2-year drawdown. Base prime and in vivo platforms are all seeing renewed conviction. X AI x Genomics is driving the rebound. Names like $TEM (+181% YTD) $RXRX (-26% YTD) $ABSI (+36% YTD) show that the next wave of genetic medicine is data-native where models not mice guide discovery. X From therapy bets to ecosystem plays. Portfolio shifting from binary drug developers to scalable biology infrastructure. Top Holdings"
X Link @BowTiedBiotech 2025-10-12T14:02Z 20.9K followers, 14.3K engagements

"Kailera Therapeutics Announces $XXX Million Series B Financing It will be entertaining when they get acquired before $VKTX 🤣 Although if someone was going to make a move they would have done it before this money went in and I assure you that idea was directly tested with pharmas (i.e. financing was plan B)"
X Link @BowTiedBiotech 2025-10-14T14:40Z 20.9K followers, 5501 engagements

"🧠 Is Obicetrapib the Next Breakthrough in Alzheimers NewAmsterdam Pharma $NAMS is about to test a bold thesis.can CETP inhibition alter the course of Alzheimers in genetically high-risk patients In our latest BowTiedBiotech research note we unpack the upcoming Q3 2025 readout from NAMSs Phase X Alzheimers sub-study. This trial is the first serious attempt to reposition a cardio drug (obicetrapib) as a disease-modifying agent for ApoE4 carriers targeting upstream lipid dysregulation that may drive neurodegeneration. 📉 Whats at stake The primary endpoint is plasma p-tau217 a validated"
X Link @BowTiedBiotech 2025-07-28T09:30Z 20.9K followers, 6160 engagements

"Broadway vs Hollywood Meets Biotech Investing Ep. XXX Venture capital runs on chaos. Hedge funds run on control. Both make money. Biotech lives where those worlds collide. The tension you see every day on X (the ego the snark the skepticism vs belief) isnt personal. Its psychology. Each side is wired for a different kind of variance. Learn how variance drives returns and how top investors manage it. 🔗"
X Link @BowTiedBiotech 2025-10-12T12:32Z 20.9K followers, 1546 engagements

"🤑BMS Buys Orbital for $1.5B.In Vivo CAR-T Arms Race Heats Up $BMY is acquiring Orbital Therapeutics for $1.5B cash adding an RNA-LNP in vivo CAR-T platform (lead: OTX-201 pre-IND CD19 program). 🕵Deal Comps Follows $ABBV / Capstan ($2.1B; non-viral) and $GILD / Interius ($350M; viral) Orbital sits between them on stage (pre-IND) and valuation (platform-weighted) Validates appetite for delivery + design-layer RNA stacks as next-gen cell therapy infrastructure 🗣Full FOMO: Big Pharma is converging on in vivo reprogramming as the next cell therapy frontier. Capstan set the high bar"
X Link @BowTiedBiotech 2025-10-10T12:09Z 20.9K followers, 3527 engagements

"3/ Think of it as a genetic volume knob. AAV deliver once at Low. If biomarkers lag inject an LNP mRNA booster encoding Cre to step it to Med. No second viral vector no long-term drug. For the first time dose escalation becomes an edit not an infusion"
X Link @BowTiedBiotech 2025-10-14T00:22Z 20.9K followers, XXX engagements

"(UPDATED) US PHARMA MANUFACTURING COMMITMENTS 8.22.25 Johnson & Johnson $JNJ$57B Roche $RHHBY$50B AstraZeneca $AZN$50B Eli Lilly $LLY$50B Sanofi $SNY$20B Gilead $GILD$32B Takeda $TAK$30B Novo Nordisk $NVS $23B Novartis $NVF $23B Merck $MRK$9B Biogen $BIIB$2B Thermo Fisher $TMO$2B Amgen $AMGN$900M AbbVie $ABBV$195M 🤑TOTAL$349.1 B"
X Link @BowTiedBiotech 2025-08-22T11:03Z 20.9K followers, 12.4K engagements

"Reading between the lines : X R&D Priorities Under Howard Chang $AMGN X Unlock the dark genome Target non-coding DNA & lncRNAs like Xist for autoimmune B-cell reset. X Genetics + real-world data Double success odds by validating targets via deCODE-scale human genomics. X Modality-agnostic delivery siRNAantibody conjugates to hit tissues beyond liver (e.g. MariTide GLP-1+GIP). X Modular therapeutics Plug-and-play T-cell engagers & degraders for multi-pathway control. X ecDNA in cancer Go after oncogene cargo (KRAS) & synthetic lethality in 1/3 of tumors"
X Link @BowTiedBiotech 2025-08-14T15:00Z 20.9K followers, 2578 engagements

"1/ Inflammation = Next CV Growth Driver $NVS buys $TRML for $1.4B Tourmalines pacibekitug is a Phase 3ready antiIL-6 antibody for ASCVD. Novartis is betting on residual inflammatory risk as the next frontier in heart disease. Pacibekitug looks differentiated. Monthly or quarterly dosing. XX% median hs-CRP reduction in Phase X. Clean safety. Clear path into outcomes trials. Deal maths: -Peak proj PYS $35B -Risk adjusted $1.31.5B -Paid $1.4B -1.0x risk adj 0.35x peak For context Novo paid $2.1B for Corvidia in 2020 at an earlier stage. Novartis is paying less for a later cleaner asset. Textbook"
X Link @BowTiedBiotech 2025-09-09T11:15Z 20.9K followers, 3148 engagements

"Biotechs Next Catalyst: Jazz Bets on Dordaviprone $JAZZ Ep. XXX PDUFA Preview On August XX the FDA will rule on dordaviprone a first-in-class dopamine D1 receptor agonist for H3 K27M-mutant diffuse midline glioma (DMG) a uniformly fatal pediatric brain cancer with no approved therapies. The setup ✅ Huge unmet need ❌ Weak dataset Dordaviprones NDA is stitched together from five open-label single-arm trials with no control arm and limited radiographic response durability. The signal is therebut thin. The mechanism Promising but unproven. And the stakes A CRL and reputational damage if it"
X Link @BowTiedBiotech 2025-08-04T10:59Z 20.9K followers, 6610 engagements

"Top XX Pharma M&A Projections Brought To You By Grok Top XX Takeover Predictions: X Viking Therapeutics ( $VKTX $5B GLP-1) VK2735 could appeal to $LLY X Structure Therapeutics ( $GPCR $2B GLP-1) Oral GSBR-1290 fits $PFE needs X Hanmi Science ( KOSDAQ:128940 $3B GLP-1) Strong IP could attract $SNY X Zealand Pharma ( CPH:ZEAL $4B GLP-1) Innovative pipeline suits $GSK X BioAtla ( $BCAB $1.5B immuno-oncology) Target diversity fits $MRK model X ImCyse (Private $1B immunology) Precision immunology right for $RHHBY X Rubius Therapeutics (Private $2B radiopharma) Early but intriguing could suit $AMGN"
X Link @BowTiedBiotech 2025-05-15T11:22Z 20.9K followers, 13.6K engagements

"Big pharma is starting to figure it out trading pricing for predictabilityand the market loves it. $XBI $PFE $AZN Lock in a few years of tariff relief Commit to USA investment Offer discounts where margins dont matter Follow these rules and you will walk away with what every capital-heavy business craves.certainty"
X Link @BowTiedBiotech 2025-10-14T01:41Z 20.9K followers, 2352 engagements

"Pharma company Sanofi increases VC fund to $1.4bn What are they investing in 1Next-gen platforms: Gene therapy delivery (SpliceBio) protein engineering (Attovia Granite) novel RNA (Atalanta) radiopharma (AdvanCell). 2Immunology & neuro focus: Heavy cluster around autoimmune/neuroinflammation (Therini Granite Abcuro Attovia) and neurodegeneration (Atalanta Therini Character). 3Rare/underserved indications: Glycomine (ultra-rare PMM2-CDG) Abcuro (inclusion body myositis) Curevo (better shingles vaccine). 4De-risked modality bets: Stacking into validated modalities (monoclonal antibodies small"
X Link @BowTiedBiotech 2025-09-24T17:16Z 20.9K followers, 2492 engagements

"$AZN mega-blockbuster factory"
X Link @BowTiedBiotech 2025-09-07T16:11Z 20.9K followers, 7147 engagements

"Now +70% with room to run. $SLDB Didnt even wait for the standard 4:30pm to announce the follow on The usual players: Adage Capital Partners LP Bain Capital Life Sciences Invus Perceptive Advisors RA Capital Management TCGX Venrock Vestal Point Capital a U.S.-based life-sciences focused institutional investor a major mutual fund and a large investment management firm IYKYK 😜 👇🏼 .a U.S.-based life-sciences focused institutional investor"
X Link @BowTiedBiotech 2025-02-18T12:36Z 20.9K followers, 4435 engagements

"in-vivo CAR-T Economics: CAR-T used to mean personalized powerful and prohibitively expensive. A single autologous therapy can cost up to $500K per patient with manufacturing COGS still hovering around $100K even after years of optimization. Cesare Di Nitto on the HR app shared insight from EsoBiotec which shows why that math may soon collapse. 🧮 The New Equation: X LVV batch 120+ patients COGS: $10K per patient Turnaround: X week ❗No apheresis no lymphodepletion Thats a 5-10x reduction in cost per treatment achieved by moving from bespoke cell manipulation to in-vivo gene delivery. And the"
X Link @BowTiedBiotech 2025-10-12T12:39Z 20.9K followers, 16.1K engagements

"#ESMO25 Sentiment Index - What oncologists are excited about X $AZN (AstraZeneca) X $RHHBY (Roche) X $MRK (Merck & Co.) X $NVS (Novartis) X $AKESY (Akesobio) X $LLY (Eli Lilly) X $AMGN (Amgen) X $GILD (Gilead) X Sichuan Kelun Pharma 🔟 $PFE (Pfizer)"
X Link @BowTiedBiotech 2025-10-14T12:11Z 20.9K followers, 3303 engagements

"Based on below there is negative readthrough from $SMMT to $PFE 3SBiobut I am surprised by how many agree with the statement. End of day this product appears approvable there is still much room to work in terms of future study designs. Maybe not a HR but a handful of singles can still put runs on the board"
X Link @BowTiedBiotech 2025-09-08T12:04Z 20.9K followers, 5261 engagements

"4/ In CAR-T and Treg therapies DIAL is a built-in safety clutch. You start Low to reduce CRS risk. If tumor control stalls one transient pulse drives cells to Med. The new level persists through divisions stable heritable predictable. Thats the next evolution of controllable cell therapy"
X Link @BowTiedBiotech 2025-10-14T00:22Z 20.9K followers, XXX engagements

"BIOTECH MARKET RESEARCH $AGIO Ep. XXX Agios heads into a late-2025 binary with mitapivat in SCD a readout that could rewrite the standard of care or erase years of work overnight. The setup: an oral PKR activator that revs red-cell metabolism lifts hemoglobin and cuts hemolysis. If it also trims crisis rates Agios owns the SCD market Pfizer left behind when voxelotor fell. Options are already pricing XX% implied volatility into the event. Subscribe to stay ahead of the next move"
X Link @BowTiedBiotech 2025-10-13T09:30Z 20.9K followers, 1504 engagements

"Weekly Biotech News Fix Ep. XXX 🤖 Listen to the AI robots debate this weeks top news 📣🎙 TODAYS PODCAST: 0:07 Welcome 2:11 $NVO buys $AKRO for MASH 3:33 Zenas & InnoCare autoimmune 4:52 $PFE wins $MTSR 6:11 ACIP meetings delayed 7:33 FDA pauses NDAs 9:29 BI earns IPF approval 10:22 $SNY radiopharma 11:10 ARPA-H funds mRNA CAR T 12:55 $TAK exits cell therapy 🔗 links to podcast: Substa*ck Spotfy:"
X Link @BowTiedBiotech 2025-10-11T13:30Z 20.9K followers, 1395 engagements

"BIOTECH MARKET RESEARCH $ALEC Ep. XXX Another Biotech Binary Alector is heading toward a make-or-break moment with Phase X INFRONT-3 data for latozinemab in FTD-GRN expected mid-Q4 2025. ✅ success = first disease-modifying therapy in FTD ❌ If not = 's on if SORT1 blockade suffucient With no approved therapies and options implying XXX% move this one will test if biomarker restoration can truly translate into functional rescue. Subscribe to stay ahead of the next binary:"
X Link @BowTiedBiotech 2025-10-06T09:30Z 20.9K followers, 1853 engagements